Efficacy and safety of paliperidone palmitate 3-monthly versus 1-monthly formulation in Asian patients with schizophrenia: Subgroup analysis of a randomized, double-blind, noninferiority study

被引：0
|
作者：
Savitz, A. [1 ]
Gopal, S. [1 ]
Xu, H. [1 ]
Zhuo, J. [2 ]
Yu, L. [2 ]
Nuamah, I. [1 ]
Wu, C. [2 ]
Hough, D. [1 ]
Mathews, M. [1 ]
Feng, Y. [2 ]
机构：
[1] Janssen Res & Dev, Titusville, NJ USA
[2] Janssen Res & Dev, Beijing, Peoples R China
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2016年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PM419
引用
收藏
页码：201 / 201
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of paliperidone palmitate 6-monthly long-acting injectable in reduction of relapses in patients with schizophrenia: An Asian subgroup analysis of phase 3, randomized study
    Richarz, Ute
    Han, John
    Bai, Ya-Mei
    Chen, Eric Yu-Hai
    Chung, Young Chul
    Jhanwar, Venu Gopal
    Kim, Sung-Wan
    Sulaiman, Ahmad Hatim
    Knight, Karl
    Gopal, Srihari
    MEDICINE, 2023, 102 (34) : E34623
  • [22] PALIPERIDONE PALMITATE 3-MONTHLY FORMULATION IN SCHIZOPHRENIA: BASELINE INTERIM ANALYSIS OF A NATURALISTIC, 52-WEEK, PROSPECTIVE STUDY
    Hargarter, L.
    Bergmans, P.
    Usankova, I.
    Cherubin, P.
    Peters, K.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2018, 52 : 143 - 144
  • [23] Paliperidone palmitate 3-monthly formulation in schizophrenia - baseline interim analysis of a naturalistic, 52-week, prospective study
    Hargarter, L.
    Bergmans, P.
    Usankova, I.
    Cherubin, P.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S950 - S950
  • [24] Efficacy and Safety of Paliperidone Palmitate 3-month Formulation in Schizophrenia: a Randomized, Double-blind, Placebo-controlled Study
    Berwaerts, J.
    Liu, Y.
    Gopal, S.
    Nuamah, I.
    Xu, H.
    Savitz, A.
    Coppola, D.
    Schotte, A.
    Remmerie, B.
    Maruta, N.
    Hough, D.
    EUROPEAN PSYCHIATRY, 2015, 30
  • [25] Paliperidone palmitate 3-monthly formulation in schizophrenia - baseline interim analysis of a naturalistic, 52-week, prospective study
    Hargarter, L.
    Bergmans, P.
    Usankova, I.
    Cherubin, P.
    EUROPEAN PSYCHIATRY, 2018, 48 : S107 - S108
  • [26] Determinants of Caregiver Burden in Family Carers of Asian Patients with Schizophrenia treated with Paliperidone Palmitate 3-monthly injectable
    Gopal, Srihari
    Xu Haiyan
    Savitz, Adam
    Nuamah, Isaac
    Woodruff, Kimberly
    Mathews, Maju
    Lu Yu
    Zhuo Jianmin
    Feng Yu
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 234 - 235
  • [27] Stable schizophrenia patients switched to paliperidone palmitate 3-monthly formulation in real life: impact on caregiver burden
    Maina, G.
    Garcia-Portilla, M. P.
    Llorca, P. M.
    Bozikas, V. P.
    Devrimci-Ozguven, H.
    Kim, S. W.
    Bergmans, P.
    Strulev, V.
    Cherubin, P.
    Pungor, K.
    EUROPEAN PSYCHIATRY, 2019, 56 : S262 - S262
  • [28] Stable schizophrenia patients switched to paliperidone palmitate 3-monthly formulation in real life: functioning and resource use
    Garcia-Portilla, P.
    Llorca, P. M.
    Maina, G.
    Bozikas, V. P.
    Devrimci-Ozguven, H.
    Kim, S. W.
    Bergmans, P.
    Usankova, I.
    Cherubin, P.
    Pungor, K.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S238 - S239
  • [29] A PRELIMINARY COST ANALYSIS OF SCHIZOPHRENIC PATIENTS STABILIZED ON 1-MONTHLY LONG ACTING PALIPERIDONE PALMITATE (PP1M) INJECTION SWITCHING TO PALIPERIDONE PALMITATE 3-MONTHLY FORMULATION (PP3M) IN THE PUBLIC SECTOR OF HONG KONG
    Choon, W. Y.
    Wu, D. B.
    Lee, K. K.
    VALUE IN HEALTH, 2017, 20 (09) : A711 - A711
  • [30] EFFICACY AND SAFETY OF PALIPERIDONE PALMITATE 3 MONTH FORMULATION: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Berwaerts, Joris
    Liu, Yanning
    Gopal, Srihari
    Nuamah, Isaac
    Xu, Haiyan
    Savitz, Adam
    Coppola, Danielle
    Schotte, Alain
    Remmerie, Bart
    Maruta, Nataliya
    Hough, David W.
    SCHIZOPHRENIA BULLETIN, 2015, 41 : S302 - S302
12345